Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial

By Ghosn Marwan   Kattan Joseph   Farhat Fadi   Younes Fariha   Nasr Fadi   Moukadem Walid   Gasmi Jamal   Chahine Georges  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 11-18

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer

By Esteban E.  

Breast Cancer Research and Treatment, Vol. 62, Iss. 2, 2000-07 ,pp. : 127-133

Springer Publishing Company

Access to resources Recommend Favorite

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells

By Nahta Rita   Esteva Francisco  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 2, 2004-02 ,pp. : 186-190

Springer Publishing Company

Access to resources Recommend Favorite

Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group

By Langkjer Sven   Ejlertsen Bent   Mouridsen Henning   Andersen Jørn   Møller Nielsen Mette   Åge Møller Knud   Lindegaard Madsen Ebbe   Haarh Vera  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 735-739

Informa Healthcare

Access to resources Recommend Favorite